VENN STRATEGIES

Lobbying for UCB, INC. · Biopharmaceutical company dealing in severe diseases in immunology and neurology.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Georgia

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Policies related to biopharmaceutical access and innovation.

Taxation/Internal Revenue Code

International tax, corporate tax rate, and research and development tax issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.